Macomics

Macomics is a private, pre-clinical biotech company pioneering macrophage-targeted therapies for oncology, inflammation, fibrosis, and neurology. Its core asset is the ENIGMAC™ platform, which uses human genetic and clinical evidence to identify and validate novel macrophage targets. Led by an experienced team with strong venture backing, the company aims to translate its unique understanding of macrophage biology into breakthrough treatments for diseases where current options are limited.

ENIGMAC™ platform: a proprietary discovery platform that creates genetic models of disease to uncover and validate novel macrophage-specific targets, leveraging human genetic and clinical evidence.

Competition is intensifying from large pharma and other biotechs (e.g., Jounce Therapeutics, Scholar Rock, Pioneering Medicines) exploring macrophage and myeloid cell targeting. Macomics differentiates through its dedicated focus on genetically-validated, disease-specific macrophage biology via its ENIGMAC™ platform.